<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>chronic lymphocytic leukaemia &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/chronic-lymphocytic-leukaemia/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 06 Sep 2025 12:47:06 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>chronic lymphocytic leukaemia &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Study Reveals Blood Cancer Patients on Bruton Tyrosine Kinase Inhibitors Can Safely Continue Treatment During COVID-19 Vaccination</title>
		<link>https://bioengineer.org/study-reveals-blood-cancer-patients-on-bruton-tyrosine-kinase-inhibitors-can-safely-continue-treatment-during-covid-19-vaccination/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 01 Apr 2025 18:18:49 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[blood cancer patients]]></category>
		<category><![CDATA[Bruton Tyrosine Kinase Inhibitors]]></category>
		<category><![CDATA[chronic lymphocytic leukaemia]]></category>
		<category><![CDATA[clinical trial]]></category>
		<category><![CDATA[COVID-19 vaccination]]></category>
		<guid isPermaLink="false">https://bioengineer.org/study-reveals-blood-cancer-patients-on-bruton-tyrosine-kinase-inhibitors-can-safely-continue-treatment-during-covid-19-vaccination/</guid>

					<description><![CDATA[In a groundbreaking development for patients suffering from blood cancer, recent research led by the University of Birmingham and the Oxford Clinical Trials Research Unit has provided important insights regarding the management of chronic lymphocytic leukaemia (CLL) during COVID-19 vaccination. The findings, published in the esteemed journal Lancet Haematology, indicate that patients receiving Bruton Tyrosine [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">239720</post-id>	</item>
	</channel>
</rss>
